Lupin: Biosimilars Could Drive the Next Growth Phase

is expanding its presence in the biosimilars segment and is targeting around $500 million in biosimilar revenue over the next five years. The company has already invested around ₹500 crore in the business and plans to increase the investment to approximately ₹700 crore as it scales its portfolio and manufacturing capabilities. The company recently received USFDA approval for its pegfilgrastim biosimilar, adding another product to its global portfolio. Lupin is also preparing for the commercialisation of its ranibizumab biosimilar across major international markets. The European Commission had earlier approved Lupin’s ranibizumab biosimilar, which is expected to be commercialised through Sandoz in the European Union. The opportunity is significant because biosimilars can provide access to large biologic markets while offering attractive growth potential as healthcare systems seek cost-effective alternatives to expensive biologic therapies. However, the business also requires substantial upfront investment, regulatory approvals and successful market launches.